Back to search

Cordyceps, Scarlet Club · 2022 · Review

High relevance

Potential Therapeutic Strategies for Renal Fibrosis: Cordyceps and Related Products.

Cordyceps militaris

Energy & fatigueLiver support
SpeciesCordyceps, Scarlet Club
JournalFrontiers in pharmacology
Year2022

Key points

  • At present, there is no effective drug for the treatment of renal fibrosis; in particular, a safe and effective treatment for renal fibrosis should be established
  • Cordyceps has several medical effects, including immunoregulatory, antitumor, anti-inflammatory, and antioxidant effects, and may prevent kidney, liver, and heart diseases
  • Cordyceps has also been reported to be effective in the treatment of renal fibrosis
  • In this paper, we review the potential mechanisms of Cordyceps against renal fibrosis, focusing on the effects of Cordyceps on inflammation, oxidative stress, apoptosis, regulation of autophagy, reduction of extracellular matrix deposition, and fibroblast activation
  • Available clinical studies support the possibility that Cordyceps and related products provide benefits to patients with chronic kidney diseases as adjuvants to conventional drugs
  • However, the existing clinical studies are limited by low quality and significant heterogeneity

Metadata-grounded summary

Citation abstract

At present, there is no effective drug for the treatment of renal fibrosis; in particular, a safe and effective treatment for renal fibrosis should be established. Cordyceps has several medical effects, including immunoregulatory, antitumor, anti-inflammatory, and antioxidant effects, and may prevent kidney, liver, and heart diseases. Cordyceps has also been reported to be effective in the treatment of renal fibrosis. In this paper, we review the potential mechanisms of Cordyceps against renal fibrosis, focusing on the effects of Cordyceps on inflammation, oxidative stress, apoptosis, regulation of autophagy, reduction of extracellular matrix deposition, and fibroblast activation. We also discuss relevant published clinical trials and meta-analyses. Available clinical studies support the possibility that Cordyceps and related products provide benefits to patients with chronic kidney diseases as adjuvants to conventional drugs. However, the existing clinical studies are limited by low quality and significant heterogeneity. The use of Cordyceps and related products may be a potential strategy for the treatment of renal fibrosis. Randomized controlled trial studies with good methodological quality, favorable experimental design, and large sample size are needed to evaluate the efficacy and safety of Cordyceps.

Citation

Tan W, Wang Y, Dai H, Deng J, Wu Z, Lin L, et al. (2022). Potential Therapeutic Strategies for Renal Fibrosis: Cordyceps and Related Products. Frontiers in pharmacology https://doi.org/10.3389/fphar.2022.932172 PMID: 35873549

Open citation